Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Short-term Investments (2019 - 2025)

Immunocore Holdings (IMCR) has disclosed Short-term Investments for 3 consecutive years, with $396.4 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments rose 8.72% to $396.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $396.4 million through Dec 2025, up 8.72% year-over-year, with the annual reading at $396.4 million for FY2025, 8.72% up from the prior year.
  • Short-term Investments hit $396.4 million in Q4 2025 for Immunocore Holdings, up from $393.9 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $396.4 million in Q4 2025 to a low of $354.6 million in Q2 2024.